Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES) easlfibronostg on June 29, 2026 Category: Publications Tag: Identification, LiverSTAT, MASLD, NAFLD, Screening Post navigation Previous: Previous post: LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia)Next: Next post: LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)
